Metformin treatment and evolution of endometrial cancer

Climacteric

Volumn 17, Issue 2, 2014, Pages 207-209

  Pérez López, Faustino R ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONAMIDE; SULFONYLUREA;

BODY MASS; CANCER SURVIVAL; DIABETES MELLITUS; ENDOMETRIUM CANCER; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NOTE; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84896354566     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.884273     Document Type: Note

References (13)

1. Ko E M, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2013 Nov 22. Epub ahead of print
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-78 (Pubitemid 351232031)
3. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 2012; 19: F1-8
4. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta- analysis. Endocrine 2013 May 3. Epub ahead of print
5. Friedenreich CM, Neilson H K, Lynch B M. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer 2010; 46: 2593-604
6. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers 2013 Sep 30: Epub ahead of print
7. Dreisler E, Poulsen L G, Antonsen S L, et al. E MAS clinical guide: assessment of the endometrium in peri and postmenopausal women. Maturitas 2013; 75: 181-90.
8. Pé r ez-Ló p ez FR. Endometrial cancer and adipokines. Climacteric 2013; 16: 725-6
9. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013; 62: 111-23
10. Nevadunsky N S, Van Arsdale A, Strickler H D, et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2013 Nov 2. Epub ahead of print
11. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol 2010; 116: 92-8
12. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or-independent manners. PLoS One 2013; 8: e61537
13. Iglesias DA, Yates MS, v an der Hoeven D, et al. Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther 2013 Nov 21. Epub ahead of print